Sleep and wake have global effects on brain physiology, from molecular changes 1-4 and neuronal activities to synaptic plasticity [3] [4] [5] [6] [7] . Sleep-wake homeostasis is maintained by the generation of a sleep need that accumulates during waking and dissipates during sleep [8] [9] [10] [11] . Here we investigate the molecular basis of sleep need using quantitative phosphoproteomic analysis of the sleep-deprived and Sleepy mouse models of increased sleep need. Sleep deprivation induces cumulative phosphorylation of the brain proteome, which dissipates during sleep. Sleepy mice, owing to a gain-of-function mutation in the Sik3 gene
, have a constitutively high sleep need despite increased sleep amount. The brain proteome of these mice exhibits hyperphosphorylation, similar to that seen in the brain of sleep-deprived mice. Comparison of the two models identifies 80 mostly synaptic sleep-need-index phosphoproteins (SNIPPs), in which phosphorylation states closely parallel changes of sleep need. SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs. Inhibition of SIK3 activity reduces phosphorylation of SNIPPs and slow wave activity during non-rapid-eye-movement sleep, the best known measurable index of sleep need, in both Sleepy mice and sleep-deprived wildtype mice. Our results suggest that phosphorylation of SNIPPs accumulates and dissipates in relation to sleep need, and therefore SNIPP phosphorylation is a molecular signature of sleep need. Whereas waking encodes memories by potentiating synapses, sleep consolidates memories and restores synaptic homeostasis by globally downscaling excitatory synapses [4] [5] [6] . Thus, the phosphorylationdephosphorylation cycle of SNIPPs may represent a major regulatory mechanism that underlies both synaptic homeostasis and sleep-wake homeostasis.
Homeostatic sleep regulation is a global, intrinsic and cumulative process that ultimately involves most brain cells and regions 3, 5, 7 ; this is distinct from executive switching between sleep and wake states, which is controlled by specific neural circuits 13, 14 . We hypothesize that the molecular substrates of sleep need satisfy four criteria: 1) they should be globally and similarly regulated in most brain cells or regions; 2) they should accumulate gradually during waking and dissipate through sleep; 3) they should change in parallel with sleep need in different contexts; and 4) gain or loss of these functions should cause bidirectional changes of sleep need.
Sleep deprivation increases sleep need in mice, as shown by enhanced slow wave activity (SWA) or delta power (1-4 Hz) of electroencephalography (EEG) during non-rapid-eye-movement sleep (NREMS), which declines rapidly to the baseline followed by rebound sleep in early dark phase 8, 10, 12 (Fig. 1a , Extended Data Fig. 1a -e). We recently identified a dominant mutation in Sleepy mice 12 , Sik3 Slp/+ , in which a single nucleotide substitution in the gene for salt-inducible kinase 3 (SIK3), a member of the AMP-activated protein kinase (AMPK) family 15 , causes constitutively high sleep need, manifested by elevated SWA and duration of NREMS (Extended Data Fig. 1f-i) . Sleep deprivation increases wake time, whereas the Sleepy mutation decreases wake time; yet both cause elevated sleep need. We hypothesized that cross-comparison of these contrasting models of increased sleep need would reveal specific molecular changes associated with sleep need by filtering out non-specific effects of prolonged sleep, wake and stress.
We subjected three groups of wild-type C57BL/6N mice, at Zeitgeber time (ZT) zero, to 6 h of ad libitum sleep (S6) or sleep deprivation (SD6), or 6 h of sleep deprivation followed by a 3-h recovery sleep (RS3), respectively (Fig. 1a) . We collected brains from wild-type (Sik3 +/+ ) and Sleepy (Sik3 Slp/+ ) mice at ZT12.5, the lowest point of SWA in wild-type mice (Fig. 1a) . As shown by immunoblotting with antibodies against 14 phosphorylated substrate motifs, global phosphorylation of substrates of AMPK, protein kinase C (PKC), protein kinase A (PKA) and 'ataxia telangiectasia mutated' (ATM) and ' ATM and RAD3-related' (ATR) kinases was specifically increased in brains of both Sleepy mice and wild-type SD6 mice, but was not affected by fasting (Fig. 1b, c and Extended Data Figs. 2, 3 ). By contrast, other signalling pathways, such as casein kinase II (CK2) or tyrosine kinases, were not significantly affected ( Fig. 1c and Extended Data Fig. 2 ). These observations indicate that similar kinase pathways are globally activated in Sleepy and sleep-deprived brains.
Next, we performed quantitative proteomic and phosphoproteomic studies of whole brain lysates using multiplex tandem mass tag (TMT) labelling coupled with liquid chromatography-mass spectrometry (LC-MS) [16] [17] [18] [19] (Fig. 1a) . A total of 4 proteomic and 13 phosphoproteomic experiments was performed (Supplementary Tables 1, 2 ). The amount of peptides or phosphopeptides corresponding to exon 13, which is not translated in the Sik3 Slp mutant allele, was specifically reduced by 40% in Sik3
Slp/+ relative to Sik3 +/+ samples (Fig. 1d , g and Extended Data Fig. 4a) ; this acted as a stringent internal control. In summary, brain proteomic analysis quantified 7,963 proteins, of which 5,280 were present in all conditions in the pairwise comparisons of SD6 and RS3 (5,769 proteins), SD6 and S6 (6,067 proteins), and Sleepy and wild-type (7,650 proteins) groups (Extended Data Fig. 4b-h Table 2a ).
Few quantified peptides or proteins showed significant changes in abundance (Q < 0.2) in the comparisons of brain proteomes between Sleepy and wild-type (0.09%; 3.5%), SD6 and RS3 (0.01%; 0%), or SD6 and S6 (0%; 0.01%) samples (Fig. 1d-f and Extended Data Letter reSeArCH Fig. 4g ), suggesting that the whole brain proteome was globally stable (Supplementary Discussion 1). By contrast, comparison of the brain phosphoproteomes showed that a sizable portion of phosphopeptides exhibited significant changes (Q < 0.2) between the SD6 and RS3 (12.4%), SD6 and S6 (4%), and Sleepy and wild-type (18.3%) conditions (Fig. 1g-j) . In sleep-deprived brains, the majority of changes in phosphorylation are increases: SD6/RS3 (3,551/4,293, 82.7%) or SD6/S6 (1,198/1,381, 86.7%) (Fig. 1h, i) . The mean abundance of 918 phosphopeptides that were changed in both SD6/RS3 and SD6/S6 groups was around 32% or around 25% lower in S6 or RS3 brains, respectively, than in SD6 brains (Fig. 1j, k) . This asymmetric increase in phosphorylation was not observed in the liver phosphoproteome after sleep deprivation (Extended Data Fig. 5) . Instead, the liver phosphoproteome showed decreases in global phosphorylation in these comparisons: SD6/S6 (1,275/2,186, 58.3%) and SD6/RS3 (286/433, 66.1%) (Extended Data Fig. 5b, c) . These studies suggest that sleep and wake have opposing effects on the brain phosphoproteome: prolonged wakefulness causes hyperphosphorylation, whereas sleep promotes global dephosphorylation of the brain proteome.
Comparison of Sleepy and sleep-deprived models reveals 329 phosphopeptides that are significantly (Q < 0.2) altered in all three (Sleepy/ wild-type, SD6/S6 and SD6/RS3) comparisons (Fig. 1j) . On the basis of the mean abundance of each of these 329 phosphopeptides, unsupervised cluster analysis groups Sleepy samples with SD6 samples, whereas wild-type samples cluster with S6 and RS3 samples (Fig. 1l) . We used antibodies against specific phosphorylation sites to confirm hyperphosphorylation of multiple proteins in both Sleepy and SD6 samples (Extended Data Fig. 4i, j) . These results suggest that Sleepy mutant brains exhibit a global hyperphosphorylation of proteins, mimicking that seen in sleep-deprived brains.
Protein functions can be switched on or off by site-specific phosphorylation, or modulated by cumulative phosphorylation of multiple sites [20] [21] [22] [23] . We noted a group of proteins containing multiple phosphorylation sites that appear to be co-ordinately regulated in both Sleepy and SD6 models (Extended Data Fig. 6a, b) . For example, the synaptic vesicle protein synapsin-1 contains multiple functionally important phosphorylation sites 21, 22 , almost all of which are hyperphosphorylated in brains of sleep-deprived or Sleepy mice ( Fig. 2a and Extended Data Fig. 6a ). We measured overall phosphorylation state change (∆Ps) of synapsin-1 by calculating the sum of log 2 (fold change) values of all significantly (Q < 0.2) changed synapsin-1 phosphopeptides. Synapsin-1 has ∆Ps values of 7.5, 5.5 and 13.7 in the SD6/RS3, 
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Relative abundance Letter reSeArCH Letter reSeArCH SD6/S6 and Sleepy/wild-type comparisons, respectively (Fig. 2a) . Hyperphosphorylation of synapsin-1 in Sleepy and SD6 brain lysates was confirmed by phospho-tag gel electrophoresis (Fig. 2b) .
Next, we performed global phosphorylation state change analysis for all quantified phosphoproteins in our datasets (Fig. 2c-e and  Supplementary Table 3 ). In the sleep-deprived model, the phosphorylation state of 151 and 45 proteins is significantly upregulated (hyperphosphorylated, ∆Ps > 2.4) in SD6 brains relative to RS3 or S6 brains, respectively ( Fig. 2c, d ). The phosphorylation state of 190 proteins is significantly upregulated, whereas the phosphorylation state of 52 proteins is downregulated (hypophosphorylation, ∆Ps < −2.4) in the brains of Sleepy mice in comparison to those of wild-type mice (Fig. 2e) . Cross-comparison of sleep-deprived and Sleepy models identified 80 hyperphosphorylated proteins, which we termed the sleep-needindex-phosphoproteins (SNIPPs), whose cumulative changes in phosphorylation state parallel those of sleep need in both models (Extended Data Fig. 7a) .
Notably, 69 (>86%) of the 80 SNIPPs are annotated as synaptic proteins ( Table 4a ). Furthermore, we analysed published phosphoproteomic data of post-synaptic density (PSD) fractions from mouse forebrains collected in normal sleep (S4) and wake (W4) states 4 ( Fig. 2h and Supplementary Table 5 ). Approximately 70% of phosphorylation changes observed in PSD fractions are increases, and the mean ∆Ps value of the 80 SNIPPs is significantly increased in accordance with higher sleep need in wake brains relative to sleep brains ( Fig. 2i and Extended Data Fig. 6c, d ). These observations suggest a potential mechanistic link between the synaptic phosphoproteome and homeostatic sleep regulation (Supplementary Discussion 2).
Because synaptic activities underlie waking experience, we hypothesize that SNIPPs track waking experience through cumulative phosphorylation. To test this hypothesis, we conducted a time-course sleep deprivation followed by quantitative phosphoproteomic analysis (Fig. 3a) . Comparison of SD1, SD3 or SD6 and SD0 samples reveals a time-dependent increase in the number of phosphorylation events in whole-brain phosphoproteome (Fig. 3b) . ∆Ps analysis indicates that the mean phosphorylation states of 80 SNIPPs gradually rise with the duration of sleep deprivation (Extended Data Fig. 6e) , with many SNIPPs showing time-dependent cumulative phosphorylation (Fig. 3c , class A-C).
MK801, a specific inhibitor of N-methyl-d-aspartate receptor (NMDAR), has previously been identified as a potent inducer of SWA in rodents [24] [25] [26] . Our quantitative phosphoproteomic analysis of this pharmacological model identified 31 hyperphosphorylated proteins (∆Ps > 2.4) in the MK801 model compared to vehicle-only control, of which 25 (80%) are annotated as synaptic proteins (Fig. 3d, e and Extended Data Fig. 8 ). The MK801, Sleepy and sleep-deprived models have 21 SNIPPs in common (Extended Data Fig. 8j ), 13 of which accumulate phosphorylation in a time-dependent manner (Fig. 3f) . These 13 SWA-SNIPPs not only serve as a reliable molecular indicator of SWA or sleep need in multiple models, but also may contribute critically to regulation of SWA, a macro-electrophysiological readout of synaptic functions 5, 7 (Supplementary Discussion 3). To examine whether SNIPPs are substrates of SLEEPY (the protein encoded by Sik3 Slp ), we compared the interactomes of SLEEPY and wild-type SIK3 by immunoprecipitation and mass spectrometric analysis using whole-brain lysates from Flag-HA-Sik3
Slp and Flag-HA-Sik3 + knock-in mice 12 (Extended Data Fig. 9a and Supplementary Table 6 ). SLEEPY preferentially associated with synaptic proteins, including 28 of 80 SNIPPs (Fig. 4a and Extended Data Fig. 9b, c) . Immunoprecipitation and western blotting confirmed enhanced associations between SLEEPY and SNIPPs such as the pre-synaptic active zone protein bassoon, synaptic RAS GTPase-activating protein 1 (SYNGAP1) and NMDAR subunits NR2B and NR1 (Fig. 4b) .
We applied the AMPK Motif Analyzer to predict 2,943 phosphopeptides as potential AMPK substrates 27 in the Sleepy/wild-type phosphoproteome dataset (Extended Data Fig. 9d and Supplementary Fig. 9e ). Recombinant SLEEPY and SIK3 exhibited similar in vitro kinase activities (Extended Data Fig. 9f ), suggesting that SLEEPY itself does not have increased kinase activity. Taken together, these observations suggest that SLEEPY may increase phosphorylation of SNIPPs by enhancing kinase-substrate association. Next, we attempted to rescue the phenotypes of Sleepy mice by intracerebroventricular injection of the pan-SIK inhibitor HG-9-91-01 28 (HG) to inhibit SLEEPY or SIK3 kinase activity (Fig. 4c) . Administration of HG significantly reduced phosphorylation of AMPK substrates, particularly phosphorylation of the 28 SLEEPY-interacting SNIPPs (Extended data Fig. 9g-i) . Consistent with this, HG treatment of Sleepy mice reduced phosphorylation of SNIPPs and SWA, but not duration, of NREMS (Fig. 4d, e , h, i and Extended Data Fig. 9j-m) . Similarly, HG treatment of sleep-deprived wild-type mice reduced phosphorylation of AMPK substrates, phosphorylation of SNIPPs and SWA of NREMS (Fig. 4f , g, j, k and Extended Data Fig. 10 ), suggesting that SIK3 and SNIPPs have a critical role in normal homeostatic sleep regulation.
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We hypothesize that a core set of SNIPPs monitor the duration and richness of prior waking through cumulative phosphorylation, which translates into a corresponding sleep need that determines the quality and duration of subsequent sleep 11 ( Fig. 4l and Supplementary Discussion 4). Whereas prolonged wakefulness leads to cognitive impairment and sleepiness, sleep refreshes the brain through multiple restorative effects and optimizes cognitive functions for the next waking period 5, 7, 9, 11 . Specifically, the synaptic homeostasis hypothesis posits that waking encodes memories by potentiating synapses, whereas sleep consolidates memories and restores synaptic homeostasis by global downscaling of synaptic strength 5 . We hypothesize that the phosphorylation-dephosphorylation cycle of SNIPPs represent a major regulatory mechanism that underlies both synaptic homeostasis and sleep-wake homeostasis to maximize cognitive functions of the brain.
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MEthodS
General materials. Tandem mass tag (TMT) isobaric reagents, water and organic solvents were purchased from Thermo Fisher Scientific. Titansphere titanium dioxide (TiO 2 ) beads were from GL Sciences. Phospho-tag was from Wako Pure Chemical Industries. Unless otherwise noted, all other chemicals were from SigmaAldrich or Nacalai Tesque. Animal studies. All animal experiments were performed according to procedures approved by the Institutional Animal Care and Use Committee of University of Tsukuba or University of Texas Southwestern Medical Center at Dallas. All mice used were males on a C57BL/6N background and were housed under humidityand temperature-controlled conditions (22-25 ± 1 °C) on a 12-h light-dark cycle. Food and water were provided ad libitum. Sleep phenotype analysis. The sleep-wake behaviours were analysed as previously described with modifications 12 . Electroencephalogram (EEG)/electromyogram (EMG) data were visualized and analysed using a custom semi-automated staging MatLab (MathWorks)-based program, followed by visual inspection. We did not apply blinding and only excluded animals with unreadable EEG signals from final sleep analysis. In brief, mice were implanted with the EEG/EMG electrodes at the age of 8-10 weeks, and EEG/EMG signals were recorded during weeks 12-20. Age-matched control and treatment groups of animals were used for each experiment. Following semi-automated analysis of EEG/EMG data, EEG signals were subjected to fast Fourier transform analysis for 1 to 30 Hz with 1-Hz bins. Wake was defined by low amplitude, fast EEG and high amplitude, variable EMG; NREMS by high amplitude, delta (1-4 Hz) frequency EEG and low EMG tonus; and REMS by dominant theta (6-9 Hz) frequency EEG and EMG atonia. Absolute and relative power spectrum analyses of corresponding states within indicated ZT times were performed; for relative power spectrum analysis (%), the EEG power of each frequency bin was expressed as a percentage of the total power over all frequency bins (1-30 Hz). Absolute NREMS delta power density (arbitrary units) is determined by the delta band of NREMS and normalized to the average NREMS delta power during ZT8 to ZT11 of the baseline recording day 10 ; relative delta power density (%) is defined by the ratio of delta power (1-4 Hz) to total power of NREMS EEG. In circadian variation plots, each data point represents the mean value of NREMS delta power or duration in the following 1 h. Experimental design. To examine how different treatments affect sleep/wake behaviours, 3-day baseline EEG/EMG recordings were conducted after mice were acclimated for a week. Mice remained in the same recording chamber for a 3-6-day interval between treatments. No abnormal EEG/EMG signals were confirmed during the interval before next treatment.
For the sleep deprivation model, mice were sleep deprived on an automated orbital shaker with access to food and water 12 . A 1-day baseline recording taken before sleep deprivation was used as the basal condition. Whole brains or livers were collected at ZT6 for ad libitum sleep (S6) and sleep-deprived (SD6, ZT0-ZT6) wild-type mice, or at ZT9 for 6-h sleep deprivation followed by 3-h recovery sleep (RS3) wild-type mice. For time-course sleep-deprivation, whole brains of wild-type mice were collected at ZT0 (SD0) or after 1, 3 or 6 h of sleep deprivation (SD1, SD3, SD6). For the Sleepy model, baseline EEG/EMG recording data were used; whole brains were collected for Sik3 +/+ (wild-type) and Sik3 Slp/+ (Sleepy) at ZT12.5. For food/water deprivation experiments, sham deprived (old food/water exchanged for new food/water) and deprived (all food/water removed at indicated ZT) were conducted in both normal sleep and sleep-deprived conditions; whole brains were collected at ZT6 for both conditions. For MK801 treatment, we performed intraperitoneal injection of mice with vehicle (0.9% saline) followed by 2 mg/kg MK801 (Sigma-Aldrich). Wild-type mice were injected at ZT17 in the previous dark phase followed by EEG/EMG recording at the onset of light phase (ZT0); whole brains were collected at ZT23.5, 6.5 h after MK801 administration. For HG-9-91-01 28 (ApexBio) treatment, we performed intracerebroventricular injection of mice with vehicle (3% DMSO) followed by 8 mg/kg HG-9-91-01. Sik3
Slp/+ mice were injected at ZT6 and ZT9; whole brains were collected at ZT11.5. Wild-type mice were injected at ZT0 and ZT3 during sleep deprivation (ZT0-ZT6); whole brains were collected at ZT6. The organization of sleep experiments and sleep phenotype results are listed in Supplementary Table 7b . Tissue lysate preparation. Mouse tissues (whole brain or liver) were quickly dissected at indicated ZT, rinsed with PBS and flash frozen in liquid nitrogen. Typically, one mouse brain was homogenized in a glass tissue homogenizer with 5 ml of lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 2.5% SDS, 2 mM MgCl 2 ) freshly supplemented with protease and phosphatase inhibitor cocktail tablets (Roche). Tissue homogenates were incubated at room temperature for 30 min and centrifuged at 15,000g for 20 min. The supernatant was carefully transferred to a new tube without disturbing the pellet. Protein concentration of protein lysates was determined using the bicinchoninic acid (BCA) assay (Thermo Scientific Pierce).
For comparison of the SIK3 and SLEEPY interactomes, wild-type, Flag-HASik3
+ and Flag-HA-Sik3 Slp knock-in mouse brains were lysed in ice-cold lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2 mM MgCl 2 , 15 mM NaF, 10 mM Na 4 P 2 O 7 ) freshly supplemented with protease/ phosphatase inhibitors in a glass tissue homogenizer 12 . After 30 min incubation on ice, brain homogenates were centrifuged at 13,000g for 20 min at 4 °C. The supernatant was pre-cleared with IgG and Protein G beads for 30 min before immunoprecipitation. 50 μl of anti-Flag antibody-conjugated Sepharose beads (A2220, Sigma-Aldrich) was added to each pre-cleared lysate and rotated overnight at 4 °C. The beads were washed five times with cold wash buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2 mM MgCl 2 , 15 mM NaF, 10 mM Na 4 P 2 O 7 ), 50 μl of elution buffer (2% SDS, 60 mM Tris-HCl, pH 6.8, 50 mM dithiothreitol (DTT), 10% glycerol) was then added and rotated for 10 min at 4 °C. Protein elution was repeated twice and combined into one eluate, then analysed by mass spectrometry and western blotting. Mass spectrometry sample preparation. Protein lysate sample was reduced with DTT and then alkylated with iodoacetamide. Chloroform-methanol precipitation of protein lysate was performed, and the precipitate was resuspended in 8 M urea buffer. Protein lysate was digested for 2 h with Lys-C (1:100, enzyme to protein; Wako), followed by dilution to 2 M urea with 25 mM ammonium carbonate buffer (pH 7.8), and trypsin (1:100, enzyme to protein; Thermo Scientific Pierce) digestion overnight at room temperature. After stopping the digestion with 1% formic acid, the peptide mixture was subjected to C18 solid-phase extraction (Sep-Pak, Waters) for desalting, and subsequently vacuum-centrifuged to near-dryness.
For phosphopeptide enrichment, desalted peptides were resuspended in 1 ml phosphopeptide binding buffer (2 M lactic acid/50% acetonitrile (ACN)) and centrifuged at 15,000g for 20 min at room temperature. The supernatant was carefully transferred to a new tube without disturbing the pellet. TiO 2 beads were washed three times with phosphopeptide binding buffer, added to the supernatant (peptide mixture) and incubated with gentle rotation for 1 h at room temperature. Afterwards, TiO 2 beads were washed twice with phosphopeptide binding buffer and twice with wash buffer (50% ACN/0.1% trifluoroacetic acid). Phosphopeptides were eluted twice from TiO 2 beads with 500 μl elution buffer (50 mM K 2 HPO 4 , pH 10), acidified with 20% formic acid, subjected to desalting and vacuumcentrifuged to near-dryness.
Desalted peptides were resuspended in 200 mM HEPES (pH 8.5) and peptide concentration was determined using the BCA assay. Approximately 50 μg of peptides for each sample were labelled with TMT reagent for 1 h at room temperature. After the reaction was quenched with hydroxylamine, all TMT-labelled samples for one experiment were combined into one mixture, acidified with 20% formic acid, desalted and vacuum-centrifuged to near-dryness. The TMT-labelled sample mixture was solubilized in HPLC buffer A (1% ACN, 10 mM ammonium bicarbonate, pH 8.0) for HPLC fractionation using an Agilent 300 Extend C18 column (5-μm particles, 4.6-mm internal diameter, 150 mm in length). Different HPLC fractions were acidified with 20% formic acid and vacuum centrifuged to near-dryness. Each fraction was desalted using a StageTip, dried by vacuum centrifugation and re-suspended for LC/MS analysis. Mass spectrometry data acquisition. Data were collected using the OrbitrapFusion mass spectrometry platform coupled with EASY-nLC 1000 liquid chromatography pump (Thermo Fisher Scientific). A pre-column (Acclaim PepMap 100 C18, Thermo Fisher Scientific) and analytical column (NTCC-360/75-3-125, NIKKYO) were used for sample trapping and analytical separation. Peptides were separated at a flow rate of 300 nl/min using a gradient of 6-27% ACN (0.1% formic acid) over 190 min.
The MultiNotch synchronous precursor selection MS 3 -based TMT method was used on an Orbitrap-Fusion mass spectrometer using Xcalibur (v.3.0; Thermo Fisher Scientific) as described with modifications [16] [17] [18] [19] . In brief, first stage of mass spectrum data between 400-1500 m/z were acquired from the Orbitrap at 120,000 resolution in profile data type with 4e5 AGC target, 50-ms maximum injection time. Ions were isolated in top speed mode using the quadrupole with a 0.7-m/z isolation window. MS 2 scans between 400-1200 m/z were acquired from the ion trap in centroid data type with CID fragmentation (35% collision energy) in Turbo mode, 1e4 AGC target, 50-ms maximum injection time. Top ten MS 2 fragment ions were selected using synchronous precursor selection mode for TMT reporter ions quantitation. MS 3 scans were acquired from the Orbitrap at 60,000 resolution in profile data type with HCD fragmentation (65% collision energy), 1e5 AGC target, 120-ms maximum injection time. Ions were not accumulated for all parallelisable time. Mass spectrometry data analysis. Raw mass spectrometry files from the entire study were searched against a composite target/decoy database using SEQUEST [29] [30] [31] from Proteome Discoverer software (PD, v.2.1, Thermo Fisher Scientific). The target mouse protein database was generated from UniProt, combining all Swiss-Prot and TrEMBL entries (17 October 2015) . MS 2 spectra were searched with ± 20 ppm for precursor ion mass tolerance, ± 1 Da for fragment ion mass tolerance, fully tryptic restriction, four maximal missed cleavages, dynamic mass shift for oxidation of methionine (+15.9949 Da), fixed TMT modifications on the N terminus and lysine (+229.1629 Da), and carbamidomethylation of Letter reSeArCH cysteine residues (+57.0215 Da). For phosphoproteomic analysis, additional dynamic modifications on serine, threonine and tyrosine (+79.9663 Da) were used. The peptide spectrum matches (PSMs) were filtered by Percolator 32 (PD 2.1) to achieve 1% protein and peptide FDR (according to Q value) for proteome and phosphoproteome, respectively. ptmRS 33 (PD 2.1) was used for phosphorylation site localization, which derived a localization probability score for each putatively modified site based on the given MS 2 data. Phosphopeptides with phosphorylation site probability score ≥ 25 were considered in following analysis.
TMT reporter ion signal-to-noise (S/N) values were quantified from MS 3 scans using an integration tolerance of 20 ppm (Orbitrap) with the most confident centroid setting (PD 2.1) for matching peptides. For interactome analysis, raw reporter ion abundance was used for further analysis. For proteomic and phosphoproteomic analysis, the sum of raw reporter ion for each channel was normalized assuming equal input loading of all channels. The sum of reporter ions for each protein was used in protein quantitation. The normalized quantification data of all quantified proteins, peptides or phosphopeptides were used for further analysis.
To evaluate the confidence of protein identification and quantification by PD, we used a recently developed proteomics pipeline JUMP 34, 35 (v.1.12.1) to re-process one set of proteome data (EX4, SlpWTpa2) with the above same database search and PSM filtering parameters. The consistency of protein quantification between these two pipelines was indicated by Pearson correlation, which was calculated for each PSM from proteins quantified by both pipelines. Proteomic data processing. For proteomic analysis, different isoforms were considered as different proteins for data analysis unless otherwise stated. For phosphoproteomic analysis, phosphopeptide was used for further analysis including unique and composite (containing ≥ 2 phosphorylation sites) forms. The normalized quantification data of all quantified proteins, peptides or phosphopeptides were consolidated (sum of value) to generate a unique subject ID. The consolidated abundance values were then scaled for each protein or phosphopeptide so that the average abundance was one. The scaled data from different TMT-multiplex experiments for the same comparison (for example, Sleepy/wild-type group) were integrated together based on unique subject ID. The multiple unpaired t-test (P value) analysis followed by the two-stage step-up FDR (Q value) approach was used to determine statistical significance (Q < 0.2) for each comparison 36 . The mean value for each experiment condition was used to generate the log 2 (fold change) value for each unique subject, which was used for further analysis. To evaluate phosphorylation stoichiometry 37 , phosphoproteome normalization was performed for SD6/RS3, SD6/S6 and Sleepy/wild-type groups for which whole proteome and phosphoproteome data were available. In brief, the scaled phosphopeptide abundances of SD6 and Slp groups were adjusted with the mean abundance fold-change value of corresponding protein. Pearson correlation of log 2 (fold change) value between normalized and un-normalized was performed to evaluate the normalization effect. The full description and datasets for all proteomic experiments are listed in Supplementary Table 1, and those for all phosphoproteomics  experiments are listed in Supplementary Table 2 .
For SIK3 and SLEEPY interactome analysis, raw abundance data of all quantified proteins were consolidated (sum of value) to generate unique subject IDs, and then normalized assuming equal SIK3/SLEEPY protein amount in all channels. Two criteria were used to define the interacting protein ( [38] [39] [40] . All 22,262 genes of Mus musculus in the database were used as reference to determine the fold enrichment. Fisher's exact with FDR multiple test correction was used to determine statistical significance. The full description and datasets are listed in Supplementary Table 6 . Protein phosphorylation-state analysis. The phosphorylation state change (∆Ps) value for individual proteins is calculated as the sum of log 2 (fold change) value of all phosphopeptides with statistically significant changes (Q < 0.2) from all protein isoforms encoded by the same gene. If none of a phosphopeptide's Q values is above 0.2, the ∆Ps value will be zero. The total quantified phosphopetides number of the SD6/RS3 group was used for the ∆Ps value normalization with other comparisons of brain phosphoproteome in this study. Normalized ∆Ps value was used for further analysis to determine the hyperphosphorylated or hypophosphorylated proteins. To set up the cutoff for ∆Ps value, two null tests were performed using data from SD6/RS3 and Sleepy/wild-type phosphoproteomes, briefly, data from channels with even number between two groups were swapped to determine the FDR. For two null tests, no phosphopeptide has a Q value above 0.2 and ∆Ps value is zero for all proteins (Supplementary Table 2z , aa). Because average standard deviation (s.d.) for ∆Ps value of SD6/RS3, SD6/S6 and Sleepy/wild-type groups is 1.1 (Supplementary Table 3d ), we applied a stringent cut-off for ∆Ps value at ±2.4 (>2 s.d.) for each comparison group to represent the concept of cumulative phosphorylation. Hyperphosphorylated (hyper, ∆Ps >2.4), hypophosphorylated (hypo, ∆Ps <−2.4) phosphoproteins. The full description and datasets are listed in Supplementary Table 3. As previously described 4 , in the normal sleep-wake model, mouse forebrains (cortex plus hippocampus) were collected at ZT16 (W4) and ZT4 (S4) to purify PSD fractions for phosphoproteomic analysis. For analysis of the normal sleep-wake model, the raw phosphopeptide data from supplementary tables 2A (hyperphosphorylated during wake (10pm/10am ratio >1.3)) and S2B (hyperphosphorylated in the PSD during sleep (10am/10pm ratio >1.3, or 10pm/10am ratio <0.77)) in ref. 4 were combined into one data table. The raw quantification data of all phosphopeptides were consolidated (sum of value) to generate a unique subject ID and log 2 (fold change) value. It should be noted that no statistical test was performed for phosphopeptide comparisons as there were only two technical replicates for each condition. The ∆Ps value for each protein is calculated as the sum of log 2 (fold change) value of all phosphopeptides from all protein isoforms encoded by the same gene, which was not normalized with SD6/RS3 group. The full description and datasets were listed in Supplementary 27 . Putative AMPK phosphorylation sites (score >−0.94, the score of the lowest scoring known AMPK substrate) were used for further analysis. Complete data for AMPK substrate prediction was listed in Supplementary  Table 4c . Hierarchical clustering (centroid linkage with Euclidean distance) was performed with Cluster 3.0 67 . In vitro kinase assay. The kinase activities of recombinant SIK3 and SLEEPY proteins were measured by in vitro kinase assay as previously described 68 . A recombinant GST-MFF(S146) (136-RQNGQLVRNDSIVTPSPPQA-155; AMPK motif score = 1.06) fusion protein was used as substrate. Recombinant Flag-SIK3 and Flag-SLEEPY were overexpressed in HEK 293T cells and affinity purified with anti-Flag antibody-conjugated Sepharose beads. A mock preparation from HEK293T cells transfected with empty vector was used as negative control. The same amount of recombinant kinase and substrate proteins were incubated for 20 min at 30 °C in kinase reaction buffer (50 mM HEPES, pH 7.4, 1 mM EDTA, 10 mM MgCl 2 , 0.5 mM ATP) freshly supplemented with protease/phosphatase inhibitors. Reactions were stopped by the addition of sample loading buffer; samples were resolved by SDS-PAGE followed by western blotting or by Coomassie blue staining. Phospho-tag SDS-PAGE and immunoblotting. Equal amounts of protein samples were resolved by phospho-tag 69 (Wako) or SDS-PAGE and transferred to PVDF membrane. Phos-tag SDS-PAGE is an electrophoresis technique capable of separating phosphorylated and non-phosphorylated forms based on phosphorylation levels, owing to binding to the phospho-tag chemical, which slows the migration of phosphorylated protein 69 . The molecular weight markers are only indicative for the non-phosphorylated forms and irrelevant for the phosphorylated forms. The Rf value of 1.0 is defined as the position of bromphenol blue dye 69 .
Western blotting was performed according to standard procedures using the corresponding antibodies. Antibodies were used at the optimal concentration according to the manufacturer's instructions. Lamin A/C was measured as a loading control for the quantitative analysis of immunoblots of phosphorylation-motif antibodies. Antibodies used in this study included anti-EF2 (phospho T56/ T58) (ab82981, Abcam), anti-EF2 (#2332, Cell Signaling), anti-CaMKII (phospho T286) (ab32678, Abcam), anti-CaMKII (#4436, Cell Signaling), anti-nNOS (phospho S1417) (ab5583, Abcam), anti-nNOS (ab76067, Abcam), anti-KCC2 (phospho S940) (612-401-E15, Rockland), anti-KCC2 (07-432, EMD Millipore), anti-synapsin-1 (phospho S605) (#88246, Cell Signaling), anti-synapsin-1 (sc-8295, Santa Cruz), anti-phospho-AMPK Substrate Motif (LXRXX(S*/T*)) (#5759, Cell Signaling), anti-phospho-PKC substrate motif ((K/R)XS*X(K/R)) (#6967, Cell Signaling), anti-phospho-PKA substrate motif ((K/R)(K/R)X(S*/T*)) (#9624, Cell Signaling), anti-phospho-ATM/ATR substrate motif (S*Q) (#9607, Cell Signaling), anti-phospho-AKT substrate motif (RXX(S*/T*)) (#9614, Cell Signaling), anti-phospho-PDK1 docking motif ((F/K)XX(F/Y)(S*/T*)(F/Y)) (#9634, Cell Signaling), anti-phospho-CK2 substrate motif ((S*/T*)DXE) (#8738, Cell Signaling), anti-phospho-MAPK/CDK substrate motif (PXS*P, S*PX(K/R)) (#2325, Cell Signaling), anti-phospho-CDKs substrate motif ((K/H)S*P) (#9477, Cell Signaling), anti-phospho-PLK binding motif (ST*P) (#5243, Cell Signaling), anti-phospho-Thr-Pro motif (T*P, T*PP) (#3003, Cell Signaling), anti-phosphoThr-Pro-Glu motif (T*PE, T*P) (#3004, Cell Signaling), anti-phospho-Thr-XArg motif (T*X(K/R)) (#2351, Cell Signaling), anti-phospho-Tyr (Y*) (#8954,
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Cell Signaling), anti-Lamin A/C (sc-6215, Santa Cruz), anti-HA (Y-11) (sc-805, Santa Cruz), anti-NMDAR1 (MAB363, EMD Millipore), anti-NMDAR2B (75-101, NeuroMab), anti-SynGAP (#5539, Cell Signaling) and anti-SIK3 C-term, a custom-generated rabbit polyclonal antibody against the C-terminal 171 amino acids of mouse SIK3. Statistical methods. Unless otherwise noted, all experimental subjects are biological replicates and at least two independent experiments were performed. ImageJ software was used to quantify intensity of protein bands. GraphPad Prism 7 or R software was used for statistical tests. No statistical methods were used to predetermine sample size. Randomization and blinding were not used. Following one-way or two-way analysis of variance (ANOVA), Fisher's LSD test compares one mean with another mean; Tukey's test compares every mean with every other mean; Dunnett's test compares every mean to a control mean; Sidak's test compares a set of means. Repeated measures or paired test was performed for matched subject comparisons. P < 0.05 was considered statistically significant. The complete sample size, statistical test method and results for each comparison are reported in the figure legends and described in detail in Supplementary Table 7a . Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The mass spectrometry datasets, including raw data files, search engine files, full experimental summary file and Supplementary Tables 1 and 2 , have been deposited to MassIVE 70, 71 with accession code MSV000081865 and to Proteome Xchange with accession code PXD008558. Source Data are provided with the online version of the paper. All other datasets generated and/or analysed in the current study are available from the corresponding author on reasonable request.
1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
All raw mass spectrometry files of entire study were collected using Xcalibur (version 3.0; Thermo Fisher Scientific).
Data analysis
Mass spectrometry data (Proteome Discoverer with SEQUEST, Percolator and ptmRS , version 2.1, Thermo Fisher Scientific). Sleep data (MatLab-based custom program). Phosphorylation site score (AMPK Motif Analyzer). Hierarchical clustering (Cluster 3.0). Quantify protein band (Image J). Statistical analysis (GraphPad Prism 7 or R).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
